Aclidinium bromide

From Self-sufficiency
Jump to: navigation, search
Aclidinium bromide
File:Aclidinium bromide structure.png
Systematic (IUPAC) name
[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide
Clinical data
Routes of
administration		 Inhalational
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 320345-99-1
ATC code none
PubChem CID 11519741
Chemical data
Formula C26H30BrNO4S2
Molar mass 564.555 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Aclidinium bromide (INN) is a novel, long-acting, inhaled muscarinic antagonist currently being developed as a maintenance treatment for chronic obstructive pulmonary disease (COPD).[1] Preclinically, aclidinium showed potent antagonism of human muscarinic receptors, with a long residence time at M3 receptors and a shorter residence time at M2 receptors, indicating the potential to provide sustained bronchodilation.[2] Aclidinium is rapidly hydrolysed in human plasma, unlike other currently available antimuscarinics including tiotropium.[2][3] This results in very low and transient systemic exposure, suggesting a reduced potential for class-related systemic side effects in the clinical setting.[2][3]

Early clinical studies in healthy subjects have confirmed the low systemic bioavailability and favourable safety profile of single and multiple doses of aclidinium.[4][5] In a subsequent Phase IIb study, which included 464 patients with moderate to severe COPD, aclidinium displayed long-lasting bronchodilatory activity and was well tolerated.[6]

Aclidinium is delivered via a novel, multidose dry powder inhaler, the Genuair inhaler.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Adrenergics, inhalants
other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Combination products

M: RES

anat(n, x, l, c)/phys/devp

proc, drug(R1/2/3/5/6/7)

  1. ↑ Gavaldà A, Miralpeix M, Ramos I; et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. Epub ahead of print. 
  2. ↑ 2.0 2.1 2.2 Gavaldà A, Miralpeix M, Ramos I (2007). "Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance". Eur Respir J. 30 (suppl 51): 209S–210S. 
  3. ↑ 3.0 3.1 Gavaldà A, Sentellas S, Alberti J; et al. (2008). "Aclidinium bromide, a novel long-acting anticholinergic, is rapidly inactivated in plasma". Am J Respir Crit Care Med. 177: A–654. 
  4. ↑ Janset JM, Lamarca R, Garcia Gil E, Ferrer P. (2009). "Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects". Int J Clin Pharmacol Ther. 47: 460–468. 
  5. ↑ Janset JM, Lamarca R, de Miquel G, Schrödter A, Miletzki B, Gurniak M. (2009). "Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants". J Clin Pharmacol. Epub ahead of print. 
  6. ↑ Chanez P, Burge PS, Dahl R; et al. (2009). "Aclidinium bromide provides long-acting bronchodilation in patients with COPD". Pulm Pharmacol Ther. Epub ahead of print. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Aclidinium_bromide&oldid=23808"